Group 1 - The core viewpoint of the news is the initiation of large-scale clinical trials for gene-edited pig kidneys for human transplantation, marking a significant advancement in biotechnology and organ transplantation [1] - The first clinical trial was completed at NYU Langone Medical Center, approved by the FDA, aiming to evaluate the safety and efficacy of gene-edited pig kidneys for patients with end-stage kidney disease [1] - Global advancements in gene editing technology have been reported, including successful transplantation of gene-edited pig lungs in China and new treatment approaches for Down syndrome in Japan [1] Group 2 - Huazhong Securities highlights that breakthroughs in gene editing technology have significantly lowered the technical barriers for genetic modification, enabling large-scale industrial production of drugs [2] - In the A-share market, there are 22 listed companies with gene editing technology reserves, with mixed performance in stock prices; only 7 out of 22 companies saw gains on November 5 [4] - Among gene editing concept stocks, Shuanglu Pharmaceutical reported the highest net profit of 141 million yuan in the first three quarters, while Mengcao Ecological achieved a year-on-year profit increase of 48.73% [5][6] Group 3 - Eight gene editing concept stocks received attention from five or more institutions, with companies like Sturdy Medical and Huaxi Biological leading in institutional ratings [7] - Sturdy Medical announced a collaboration with Huazhong Agricultural University to establish a cotton research institute, focusing on gene editing and hybridization techniques for cotton seed improvement [7]

Group 1 - The core point of the news is the initiation of large-scale clinical trials for gene-edited pig kidneys for human transplantation, marking a significant breakthrough in gene editing technology [1] - The trials are approved by the FDA and aim to systematically evaluate the safety and efficacy of gene-edited pig kidneys for patients with end-stage kidney disease [1] - There have been multiple advancements in gene editing technology globally, including successful transplants of gene-edited organs and new treatment approaches for genetic disorders [1] Group 2 - Huazhong Securities notes that breakthroughs in gene editing technology have significantly lowered the technical barriers for genetic modification, enabling large-scale industrial production and reducing drug production costs [2] - A total of 22 listed companies in the A-share market have gene editing technology reserves, with several companies reporting profitability in their third-quarter results [3] - Notable companies include Shuanglu Pharmaceutical, which reported a net profit of 141 million yuan, and Mengcao Ecological, which saw a 48.73% year-on-year increase in net profit [3][4] Group 3 - Companies like Wanjian Medical are collaborating with research institutions to develop cotton varieties using gene editing technology, indicating the application of gene editing beyond human health [5] - The number of institutional ratings for gene editing concept stocks shows significant interest, with companies like Wanjian Medical and Huaxi Biological receiving the highest number of ratings [6]

Core Insights - The environmental governance sector saw an increase of 0.81% on November 3, with Zhejiang Fu Holdings leading the gains [1] - The Shanghai Composite Index closed at 3976.52, up 0.55%, while the Shenzhen Component Index closed at 13404.06, up 0.19% [1] Environmental Governance Sector Performance - Top gainers included: - Zhejiang Fu Holdings (002266) with a closing price of 4.52, up 9.98% and a trading volume of 1.93 million shares, totaling 873 million yuan [1] - Zhonghuan Environmental (300692) at 9.58, up 7.28% with a trading volume of 450,900 shares, totaling 434 million yuan [1] - Haitan Co., Ltd. (603759) at 11.74, up 6.73% with a trading volume of 370,700 shares, totaling 413 million yuan [1] - Other notable gainers included: - Feima International (002210) at 4.45, up 5.95% with a trading volume of 6.29 million shares, totaling 2.83 billion yuan [1] - ST New Power (300152) at 2.50, up 5.49% with a trading volume of 374,000 shares, totaling 9.19 million yuan [1] Fund Flow Analysis - The environmental governance sector experienced a net outflow of 772 million yuan from institutional investors, while retail investors saw a net inflow of 677 million yuan [2] - The top stocks by fund flow included: - Zhejiang Fu Holdings (002266) with a net inflow of 22.3 million yuan from institutional investors, but a net outflow of 114 million yuan from speculative funds [3] - Feima International (002210) with a net inflow of 10.7 million yuan from institutional investors, but a net outflow of 97.8 million yuan from speculative funds [3] - Yuan Da Environmental (600292) with a net inflow of 38.3 million yuan from institutional investors, but a net outflow of 14.9 million yuan from speculative funds [3]

特此公告。 浙江钱江生物化学股份有限公司董事会 2025 年 11 月 1 日 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 浙江钱江生物化学股份有限公司（以下简称"公司"）工会联合会委员会于 近日召开了 2025 年第二次代表大会，审议并通过《关于监事会不再设立后职工 监事不再任职的议案》。根据《中华人民共和国公司法》、中国证券监督管理委 员会《关于新<公司法>配套制度规则实施相关过渡期安排》《公司章程》等法律 法规、监管制度的相关要求，结合公司实际情况，公司不再设立监事会，现任职 工监事朱炳其先生自监事会正式撤销之日起不再担任职工监事。上述调整自公司 《关于增加经营范围、取消监事会并修订<公司章程>的议案》经公司股东大会审 议通过后生效。 证券代码：600796 股票简称：钱江生化 编号：临 2025—053 浙江钱江生物化学股份有限公司 关于监事会不再设立后职工监事不再任职的公告 ...

证券代码：600796 证券简称：钱江生化 公告编号：2025-051 浙江钱江生物化学股份有限公司 2025年第四次临时股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 (一)股东大会召开的时间：2025 年 10 月 31 日 (二)股东大会召开的地点：浙江省海宁市海洲街道钱江西路 178 号钱江大厦本公 司会议室 (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 1、出席会议的股东和代理人人数 | 169 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 657,496,952 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | | | 份总数的比例（%） | 75.8721 | (四)表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 本次股东大会由公司董事会召集，现场会议由公司董事长朱燕刚先生主持，会议 采用现场投票和网络投票相结合的方式表决通 ...

重要内容提示： 一、董事会会议召开情况 浙江钱江生物化学股份有限公司（以下简称"公司"）十届董事会 2025 年第 七次临时会议于 2025 年 10 月 31 日在公司会议室以现场和通讯相结合方式召开。 会议通知于 2025 年 10 月 23 日以书面及电子邮件方式发出。会议应到董事九名, 实到董事九名，董事钱宏声先生以通讯方式表决，高管列席了会议。会议由公司 董事长朱燕刚先生主持，本次会议的召开符合《公司法》及《公司章程》的规定。 证券代码：600796 股票简称：钱江生化 编号：临 2025-052 浙江钱江生物化学股份有限公司 十届董事会 2025 年第七次临时会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 二、董事会会议审议情况 （一）审议通过了《关于选举代表公司执行公司事务的董事的议案》； 表决结果：9 票同意、0 票反对、0 票弃权。 本议案无需提交公司股东大会审议。 公司取消监事会后，由审计委员会行使《公司法》规定的监事会的职权，本次董 事会确认公司第十届董事会审计委员会仍由张广冬先生、韦 ...

法律意见书 上海市锦天城律师事务所 关于浙江钱江生物化学股份有限公司 2025 年第四次临时股东大会的 锦 天 城 律师事务 所 ALLBRIGHT LAW OFFICES 地址：上海市浦东新区银城中路 501 号上海中心大厦 9/11/12 层 电话:021-20511000 邮编：200120 t on the state of the state of the state of the station of the status and the stat use alled the sin the successful hour 上海市锦天城律师事务所 法律意见书 上海市锦天城律师事务所 关于浙江钱江生物化学股份有限公司 2025 年第四次临时股东大会的 法律意见书 致：浙江钱江生物化学股份有限公司 上海市锦天城律师事务所（以下简称"本所"）接受浙江钱江生物化学股份 有限公司（以下简称"公司"）委托，就公司召开 2025 年第四次临时股东大会 （以下简称"本次股东大会"）的有关事宜，根据《中华人民共和国公司法》（以 下简称《公司法》）、《上市公司股东会规则》等法律法规、规章和其他规范性 文件以及《浙江钱 ...

Group 1 - The company Qianjiang Biochemical (SH 600796) held its 10th Board of Directors' temporary meeting on October 31, 2025, to review various proposals, including the confirmation of the Audit Committee members and the convener [1] - For the fiscal year 2024, the revenue composition of Qianjiang Biochemical is as follows: wastewater treatment and recycling at 28.2%, engineering installation and material sales at 22.76%, waste clearance and disposal at 18.53%, biological products at 14.5%, thermal power at 9.85%, and water treatment and supply at 5.43% [1] - As of the report date, Qianjiang Biochemical has a market capitalization of 5.5 billion yuan [1]

Major Events - Shanghai Zhiyuan Hengyue Technology completed the tender offer for Shangwei New Materials, acquiring 58.6232% of the shares, with trading resuming on October 30, 2025 [4] - Peking University Pharmaceutical's chairman and president Xu Xiren has been detained for criminal investigation, but the company's control and operations remain normal [5] - China Unicom's chairman Chen Zhongyue resigned due to work adjustments, effective October 29, 2025 [6][7] - CITIC Financial Assets increased its stake in Hangyang Co., Ltd. to 5% through a block trade, reflecting confidence in the company's future [8] - Haoshi Electromechanical's subsidiary plans to invest 232 million yuan in a high-end equipment intelligent manufacturing project [9] - Zhejiang Xiantong's second shareholder Li Qifu plans to invest 130 million yuan in Qiteng Robotics to enhance production capacity [10] - Qianjiang Biochemical's subsidiary has completed a project for bio-pesticide production, with an annual capacity of 3,261 tons [11] - Dongni Electronics will face risk warnings and a one-day suspension due to an administrative penalty [12] - Jindao Technology signed a strategic cooperation agreement with Hangcha Group to develop robotic joint modules [14] Performance Overview - Kweichow Moutai reported Q3 net profit of 19.224 billion yuan, a 0.48% increase year-on-year, with total revenue of 39.064 billion yuan [15] - Huibai New Materials achieved a Q3 net profit of 27.1307 million yuan, a 3066.26% increase year-on-year, with revenue growth of 49.59% [16] - Zangzi Island reported a Q3 net loss of 42.5226 million yuan, with revenue down 19.92% [17] - OFILM reported a Q3 net profit of 40.8235 million yuan, a 411.91% increase year-on-year, with revenue growth of 21.15% [18] - China Rare Earth's Q3 net profit was 30.4752 million yuan, down 26.43% year-on-year, with revenue declining 22.4% [19] - Tianqi Lithium reported a Q3 net profit of 95.4855 million yuan, turning a profit after previous losses [20] - New Yisheng's Q3 net profit was 2.385 billion yuan, a 205.38% increase year-on-year, driven by AI-related sales growth [21] - Industrial Fulian's Q3 net profit increased by 49% year-on-year [22] - CICC's Q3 net profit grew by 130% year-on-year [23] - Tianpu Co., Ltd. reported a Q3 net profit increase of 33% [24] - BlueFocus reported a Q3 net profit of 99.2389 million yuan, a 265.47% increase year-on-year [25] - Ningshui Group's Q3 net profit was 21.7388 million yuan, a 347.57% increase year-on-year [26] - Shoukai Co. reported a Q3 net loss of 3.105 billion yuan [27] - Xiamen Xiangyu's Q3 net profit was 601 million yuan, a 443.17% increase year-on-year [29] - Huaneng Intelligent reported a Q3 net loss of 53.8408 million yuan, a significant decline [30] - Zhongjin Gold's Q3 net profit increased by 39.18% year-on-year [31] - Shandong Gold's Q3 net profit increased by 92% year-on-year [32] - Yahua Group's Q3 net profit was 198 million yuan, a 278.06% increase year-on-year [33] - Western Gold's Q3 net profit increased by 168% year-on-year [34] - Laobai Gan Liquor reported a 28% decline in net profit for the first three quarters [35] - Kaiying Network's Q3 net profit was 633 million yuan, a 34.51% increase year-on-year [36] - Tongchen Beijian reported a Q3 net profit of 171 million yuan, turning a profit from previous losses [37] - Nanshan Holdings' Q3 net profit increased by 203.51% year-on-year [38] - China Merchants Bank's Q3 net profit was 38.842 billion yuan, a 1.04% increase year-on-year [39] - Huahong Technology's Q3 net profit increased by 7111% year-on-year [40] - Fangda Special Steel's Q3 net profit increased by 1368.1% year-on-year [41] Shareholding Changes - WuXi AppTec's controlling shareholder plans to reduce its stake by up to 2% [43] - Hecai Technology's major shareholder Bosch China plans to reduce its stake by up to 3% [44] Major Contracts - China Electric Power Construction signed a contract worth 6.568 billion yuan for a hospital project in Peru [45] - Lanshi Heavy Industry signed a significant contract in the nuclear energy sector worth 581 million yuan [46] - Guoke Military Industry's subsidiary signed a major sales contract worth 466 million yuan [48]

二、项目对公司的影响 浙江钱江生物化学股份有限公司 关于生物农药原药及制剂退区入园搬迁项目投产的 公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 一、项目基本情况 浙江钱江生物化学股份有限公司（以下简称"公司"）于 2023 年 2 月 27 日 召开的十届董事会 2023 年第一次临时会议，审议通过了《关于全资子公司建设 钱江生化生物农药原药及制剂退区入园搬迁项目的议案》，公司董事会同意由公 司全资子公司浙江启潮生物科技有限公司（以下简称"启潮生物"）实施建设本 项目，授权公司及启潮生物经营层全权开展本项目的建设工作。具体内容详见公 司临 2023-006 公告。 2025 年 10 月 29 日，公司接启潮生物通知，经过前期的项目建设，生物农 药原药及制剂退区入园搬迁项目已具备试运营条件。本项目主要从事赤霉酸系列 等原药及制剂及新型环保型农药制剂产品的研发及生产，通过采用先进的技术设 备，结合公司生产工艺的优化，将大幅度地提升公司的生产技术水平，达产后具 备年产规模 3,261 吨原药制剂和 2,000 万片片 ...